It was still a foolish and amateurish mistake to hire the pumpers. Caught with their hand in the cookie jar. Seems benign, foolish. As for the bashing, it's just to make money and has been extremely profitable. Welcome to the Wild West.
Yeah, well, I've been investing since the 1960s and have yet to see the SEC do anything, ever. Just saying. Totally worthless organization in my view. And shareholder lawsuits benefit the lawyers only. The last class action I was in concerned thousands in losses, and I got somthing like $14. These guys do this stuff for one two reasons - 1. Because they can, and 2. To make a bunch of money. Just my views.
Once again, it seems like Adam F and the F - wads, his followers, work for the short hedges. They go after the big run-up, when the stock is at the top of a Bollinger Band and have a multi-pronged attack to discredit, causing it to plummet right through support. It happens when the shorts get lopsided and can't get enough added shares to pummel it directly, here due to the cost to short when they were "hard to borrow" and carrying a 50% fee. There are bulls and bears in biotech, and both lie like dogs, in my view. In the end, it's the science that matters, and the due diligence you do. Unfortunately, most don't know how to assess the science and end up long or short based on what the "crips and bloods" tell them. Just street gangs making a living on the backs of others. These are my opinions. If you believe me, due your own dd, make your own decisions, and do the smartest thing you can. I'm long, but have been wrong before.
If AZC gets approved, they have an offer in on the cheap and will be well along in the process. If water permit is hopeless, it's a material adverse event. It'll be interesting to see how that timing issue gets handled. Under those conditions, it's essentially a pre-mature offer and a low ball, unless HBM is willing to take on the risk of a "fail" on water.
Check Glioma and IL12. The data in the animal models showed a "cure" which is unique in current cancer research for GBM. While a recent study showed the need to pair IL12, it appears that the ZIOP/XON data did not require such a pairing. GBM/brain cancer is a high need area with nothing new for decades, and short lifespans projected. With an open label study, IF as successful in humans as the animal model, it will make for headlines world-wide. Can you imagine someone given a few months to live and then show no signs of the disease? Gives me chills just thinking about it. Of course the caveats are a move from the animal model to the human trials and whether or not a pairing should have been used, but the advance and potential is there.
Our "up" day will be tomorrow, not today. The day of the presentation is often the "short" day, and the day after has the presentation effect. This presentation was vastly improved, and tomorrow will show it, in my view.
Vastly improved presentation, showed direction, expectations for added disclosure, work areas, timelines, data. A much improved job by Lewis. Really well done.
I'm long, but this wasn't an "amateurish" event. This was pro all the way, well coordinated, fully leveraged and highly successful, I'll wager. We're talking big money action in my opinion.
Lots of calls on a new, big, bad bear market. Hoping for a rebound, but the odds favor retrenching/correction. Often biotechs can escape the broader market's angst, but this time we seem to be leading the way. Don't like it one bit. Some news would separate us from the pack. Good news that is. Partner? Results?
The SEC is as active as a beached whale, as proactive as a politician handling the debt, and as effective as handing a condom to teen. Total waste of time. Oh, and Cramer doesn't attack anything that isn't hugging the top bollinger band. Just saying. The best revenge is to buy at these prices.
Comments about bald heads are not appropriate here. Gnomes, okay, but bald heads, no.